Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study)

Conditions

cognitive impairment

Brief summary

The main outcome variable derived from the administration of the radiopharmaceutical will be the Standardized Uptake Value Ratio (SUVR) from different PET tau images, which will be co-registered with the structural MRI image. The lower cerebellar cortex will be used as a reference region

Detailed description

SUVR values obtained for different tracers., Voxel-wise and regional correlation analysis., Transformed values to standardize tau PET tracers to a common scale., Diagnostic performance among different groups., Associations of tau tracers with amyloid., Associations of tau tracers with brain atrophy., Associations of tau tracers with cognition., Associations of tau tracers with plasma tau biomarkers (p-tau181, p-tau-217, and p-tau231)., Longitudinal tau accumulation rates among tracers., Associations between longitudinal changes in tau and amyloid deposition., Associations between longitudinal changes in tau and brain atrophy., Asociaciones entre los cambios longitudinales en tau y progresión en cognición.

Related papers

No related papers found yet.

Interventions

DRUGflorquinitau F-18

DRUGVIZAMYL 400 MBq/mL solution for injection

DRUG[18F]PI-2620

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The main outcome variable derived from the administration of the radiopharmaceutical will be the Standardized Uptake Value Ratio (SUVR) from different PET tau images, which will be co-registered with the structural MRI image. The lower cerebellar cortex will be used as a reference region	—

Secondary

Measure	Time frame
SUVR values obtained for different tracers., Voxel-wise and regional correlation analysis., Transformed values to standardize tau PET tracers to a common scale., Diagnostic performance among different groups., Associations of tau tracers with amyloid., Associations of tau tracers with brain atrophy., Associations of tau tracers with cognition., Associations of tau tracers with plasma tau biomarkers (p-tau181, p-tau-217, and p-tau231)., Longitudinal tau accumulation rates among tracers., Associations between longitudinal changes in tau and amyloid deposition., Associations between longitudinal changes in tau and brain atrophy., Asociaciones entre los cambios longitudinales en tau y progresión en cognición.	—

Measure

Time frame

SUVR values obtained for different tracers., Voxel-wise and regional correlation analysis., Transformed values to standardize tau PET tracers to a common scale., Diagnostic performance among different groups., Associations of tau tracers with amyloid., Associations of tau tracers with brain atrophy., Associations of tau tracers with cognition., Associations of tau tracers with plasma tau biomarkers (p-tau181, p-tau-217, and p-tau231)., Longitudinal tau accumulation rates among tracers., Associations between longitudinal changes in tau and amyloid deposition., Associations between longitudinal changes in tau and brain atrophy., Asociaciones entre los cambios longitudinales en tau y progresión en cognición.

—

Countries

Spain

Outcome results

None listed